If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Patient Focused Services » Patient Advocacy Groups
Download FREE Excerpt
21 Info Graphics
13 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Partnerships with patient advocacy groups are seen as an effective way to reach specific patient groups about new therapies and treatment options. Given their close relationship to patients, advocacy groups are critical partners for pharma - especially in therapeutic areas that are socially sensitive.
This research provides current benchmarks on the tools and tactics pharma organizations are using to create and maintain effective collaborations with patient advocacy groups. The study also reviews how pharma groups are measuring the performance of their advocacy role, and managing relationships with advocacy groups representing controversial disease states. The study also contains a chapter that contains qualitative data from respondents regarding advocacy collaboration. Leaders who oversee the advocacy function within pharma can use this study to compare their partnership approaches with their industry peers.
This study engaged 74 leaders supporting patient advocacy at 61 life sciences companies and organizations. More than 60% of participants are at the director/ senior director level. Nearly 65% of participants are from the United States.
Pharmaceutical; Biopharmaceutical; Biotech; Communications; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Laboratories
AbbVie; Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; BioMarin; Bionical Emas; Blue Earth Diagnostics; Bluebird Bio; Boehringer Ingelheim; Covance; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; Milestone Pharmaceuticals; MSD; Natera; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parkway Pantai; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Tillotts Pharma; UCB Pharma; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix; The Mexican Organization for Rare Disorders (OMER)
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.